![Catarina Edfjäll](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Catarina Edfjäll formerly worked at The Cancer Drug Development Forum, as Director from 2008 to 2012, International Collaboration On Rare Diseases & Orphan Drugs, as Director from 2014 to 2021, ObsEva SA, as Independent Director from 2021 to 2024, and CSL Behring AG, as Global Head-Regulatory Affairs from 2013 to 2019.
Dr. Edfjäll received her doctorate degree from the University of Basel and graduate degree from the University of Strasbourg.
Eerdere bekende functies van Catarina Edfjäll
| Bedrijven | Functie | Einde |
|---|---|---|
| OBSEVA SA | Directeur/Bestuurslid | 18-03-2024 |
International Collaboration On Rare Diseases & Orphan Drugs | Directeur/Bestuurslid | 01-01-2021 |
CSL Behring AG
 CSL Behring AG BiotechnologyHealth Technology Develops biological products | Algemeen Adviseur | 01-01-2019 |
The Cancer Drug Development Forum
 The Cancer Drug Development Forum The Cancer Drug Development Forum (CDDF) is a neutral, non-competitive multi-stakeholder platform dedicated to accelerating the development and delivery of effective cancer therapies. The private company is based in Woluwe-Saint-Lambert, Belgium. It brings together patients, academia, pharmaceutical industry members, regulatory agencies, health technology assessment bodies, and patient advocacy groups to foster collaboration, open dialogue, and knowledge sharing in oncology drug development. CDDF organizes conferences, workshops, and webinars on topics such as artificial intelligence in clinical trials, development strategies, patient access, diversity, immuno-oncology, real-world data, and pediatric cancer outcomes. The forum leads initiatives like Accelerating Clinical Trials in the EU (ACT EU) and a diversity initiative to improve clinical trial design and representativeness in research. It publishes white papers, executive summaries, reports, and guidance documents to address challenges and propose solutions for advancing cancer drug development. | Directeur/Bestuurslid | 01-01-2012 |
Opleiding van Catarina Edfjäll
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
18
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strasbourg
 University of Strasbourg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CSL Behring AG
CSL Behring AG BiotechnologyHealth Technology Develops biological products | Health Technology |
ObsEva SA
 ObsEva SA Pharmaceuticals: MajorHealth Technology Provides therapeutic treatments to increase women's reproductivity | Health Technology |
The Cancer Drug Development Forum
The Cancer Drug Development Forum The Cancer Drug Development Forum (CDDF) is a neutral, non-competitive multi-stakeholder platform dedicated to accelerating the development and delivery of effective cancer therapies. The private company is based in Woluwe-Saint-Lambert, Belgium. It brings together patients, academia, pharmaceutical industry members, regulatory agencies, health technology assessment bodies, and patient advocacy groups to foster collaboration, open dialogue, and knowledge sharing in oncology drug development. CDDF organizes conferences, workshops, and webinars on topics such as artificial intelligence in clinical trials, development strategies, patient access, diversity, immuno-oncology, real-world data, and pediatric cancer outcomes. The forum leads initiatives like Accelerating Clinical Trials in the EU (ACT EU) and a diversity initiative to improve clinical trial design and representativeness in research. It publishes white papers, executive summaries, reports, and guidance documents to address challenges and propose solutions for advancing cancer drug development. | |
International Collaboration On Rare Diseases & Orphan Drugs |
